In silico analysis of iduronate 2 sulfatase mutations in Colombian patients with Hunter Syndrome (MPSII)

Advances in Intelligent Systems and Computing

Volumn 232, Issue , 2014, Pages 205-212

  Galvis, Johanna ^a   González, Jannet ^b   Torrente, Daniel ^b   Velasco, Harvy ^a   Barreto, George Emilio ^b  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

Bioinformatic analysis; Molecular docking; Mucopolysaccharidosis II; Sulfoiduronate sulfatase

Indexed keywords

ENZYMES; MOLECULAR MODELING; PROTEINS;

BIOINFORMATIC ANALYSIS; DOCKING SIMULATIONS; LIGAND-PROTEIN INTERACTION; MOLECULAR DOCKING; MUCOPOLYSACCHARIDOSIS II; PHENOTYPE-GENOTYPE CORRELATION; STRUCTURE FUNCTIONS; SULFATASES;

BIOINFORMATICS;

EID: 84894713870     PISSN: 21945357     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-01568-2_30     Document Type: Conference Paper

References (25)

1. Neufeld, E.F., Muenzer, J.: The mucopolysaccharidoses. In: Scriver, C.R. (ed.) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York (2001)
2. Martin, R., Beck, M., Eng, C., Giugliani, R., Harmatz, P., Munoz, V., Muenzer, J.: Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121, e377-e386 (2008)
3. Wraith, J.E., Scarpa, M., Beck, M., Bodamer, O.A., De Meirleir, L., Guffon, N., Meldgaard Lund, A., Malm, G., Van der Ploeg, A.T., Zeman, J.: Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 167(3), 267-277 (2008)
4. Diez-Roux, G., Ballabio, A.: Sulfatases and human disease. Annu. Rev. Genomics Hum. Genet. 6, 355-379 (2005)
5. Saenz, H., Lareo, L., Poutou, R.A., Sosa, A.C., Barrera, L.A.: Computational prediction of the tertiary structure of the human iduronate 2-sulfate sulfatase. Biomedica 27(1), 7-20 (2007)
6. Chkioua, L., Khedhiri, S., Ferchichi, S., Tcheng, R., Chahed, H., Froissart, R., Vianey- Saban, C., Laradi, S., Miled, A.: Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II. Diagn. Pathol. 6, 42 (2011)
7. Kim, C.H., Hwang, H.Z., Song, S.M., Paik, K.H., Kwon, E.K., Moon, K.B., Yoon, J.H., Han, C.K., Jin, D.K.: Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations. Hum. Mutat. 21(4), 449-450 (2003)
8. Kato, T., Kato, Z., Kuratsubo, I., Tanaka, N., Ishigami, T., Kajihara, J., Sukegawa- Hayasaka, K., Orii, K., Isogai, K., Fukao, T., et al.: Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II. J. Hum. Genet. 50(8), 395-402 (2005)
9. Molecular Operating Environment (MOE), 2010.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 (2010)
10. Arnold, K., Bordoli, L., Kopp, J., Schwede, T.: The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22(2), 195-201 (2006)
11. Lovell, S.C., Davis, I.W., Arendall III W.B., de Bakker, P.I., Word, J.M., Prisant, M.G., Richardson, J.S., Richardson, D.C.: Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 50(3), 437-450 (2003)
12. Trott, O., Olson, A.J.: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455-461 (2010)
13. Schrödinger, L.L.C.: The PyMOL molecular graphics system, version 1.3 r 1. The PyMOL Molecular Graphics System (2010)
14. Laskowski, R.A., Swindells, M.B.: LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51(10), 2778-2786 (2011)
15. Galvis, J., Contreras, G., Correa, L., Sierra, G., Mansilla, S., Piñeros, L., Prieto, J.C., Corredor, C., Uribe, A., Velasco, H.: Identificación de mutaciones en el gen Iduronato 2 sulfatasa en pacientes colombianos con Síndrome de Hunter. Universidad Nacional de Colombia, Colombia (2012) (unpublished data)
16. Lau, K.C., Lam, C.W.: Molecular investigations of a novel iduronate-2-sulfatase mutant in a Chinese patient. Clin. Chim. Acta 392(1-2), 8-10 (2008)
17. Alves, S., Mangas, M., Prata, M.J., Ribeiro, G., Lopes, L., Ribeiro, H., Pinto-Basto, J., Lima, M.R., Lacerda, L.: Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations. J. Inherit. Metab. Dis. 29(6), 743-754 (2006)
18. Schouten, J.P., McElgunn, C.J., Waaijer, R., Zwijnenburg, D., Diepvens, F., Pals, G.: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30(12), e57 (2002)
19. Sukegawa-Hayasaka, K., Kato, Z., Nakamura, H., Tomatsu, S., Fukao, T., Kuwata, K., Orii, T., Kondo, N.: Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J. Inherit. Metab. Dis. 29(6), 755-761 (2006)
20. Negishi, M., Dong, J., Darden, T.A., Pedersen, L.G., Pedersen, L.C.: Glucosaminylglycan biosynthesis: what we can learn from the X-ray crystal structures of glycosyltransferases GlcAT1 and EXTL2. Biochem. Biophys. Res. Commun. 303(2), 393-398 (2003)
21. Villani, G.R., Daniele, A., Balzano, N., Di Natale, P.: Expression of five iduronate-2- sulfatase site-directed mutations. Biochim. Biophys. Acta 1501(2-3), 71-80 (2000)
22. Gucev, Z.S., Tasic, V., Sinigerska, I., Kremensky, I., Tincheva, R., Pop-Jordanova, N., Danilovski, D., Hofer, D., Paschke, E.: Hunter syndrome (Muccopolysaccharridosis Type II) in Macedonia and Bulgaria. Prilozi. 32(2), 187-198 (2011)
23. Feldhammer, M., Durand, S., Pshezhetsky, A.V.: Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One 4(10), e7434 (2009)
24. Schitter, G., Scheucher, E., Steiner, A.J., Stutz, A.E., Thonhofer, M., Tarling, C.A., Withers, S.G., Wicki, J., Fantur, K., Paschke, E., et al.: Synthesis of lipophilic 1- deoxygalactonojirimycin derivatives as D-galactosidase inhibitors. Beilstein J. Org. Chem. 6, 21 (2010)
25. Fantur, K., Hofer, D., Schitter, G., Steiner, A.J., Pabst, B.M., Wrodnigg, T.M., Stutz, A.E., Paschke, E.: DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts. Mol. Genet. Metab. 100(3), 262-268 (2010).